Delix Therapeutics recently announced that the first neuroplastogen drug based on UC Davis Institute for Psychedelics and Neurotherapeutics (IPN) research will be tested in patients with major depressive disorder.
The Phase 1b trial will measure biomarkers related to pharmacodynamics and neuroplasticity as well as pharmacokinetics, safety, and efficacy outcomes.
The announcement is a huge step forward for research into psychedelic analogs as well as the field of neurotherapeutics, representing an important milestone for IPN and its industrial partners.
Learn more by reading the Delix Therapeutics press release.
YOU MAY ALSO LIKE THESE STORIES
Anti-Anxiety and Hallucination-Like Effects of Psychedelics Mediated by Distinct Neural Circuits
The study, in a mouse model, shows that it could be possible to separate treatment from hallucinations when developing new drugs based on psychedelics.
Exploring the Psychedelics Within Us
UC Davis Institute for Psychedelics and Neurotherapeutics researchers are exploring the world of endogenous psychedelics while also creating a massive library of psychedelic compounds and non-hallucinogenic analogs.